MARKETS / NYSE / HLF

NYSE · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES · LARGE CAP

Herbalife Ltd. HLF

18 fiscal years on record · USD · FY2025 reported · SEC filings only

Revenue

$5.0B

▲ 0.9% YoY

Net income

$228.3M

▼ 10.2% YoY

Free cash flow

$252.9M

▲ 54.8% YoY

In brief

What this company does

Herbalife Ltd. provides weight management, targeted nutrition, energy, sports and fitness, and outer nutrition products in 95 markets around the world. It uses a direct-selling business model to distribute and market its nutrition products to and through a global network of Members. As of December 31, 2025, it had sold 144 product types. As of December 31, 2025, it had approximately 8,500 employees, of which approximately 2,200 were located in the United States. Its manufacturing facilities, known as Herbalife Innovation and Manufacturing Facilities, include HIM Lake Forest and HIM Winston-Salem in the U.S., and HIM Suzhou in China. It also has contract manufacturers strategically located in countries including India, Italy, the U.S., Brazil, South Korea, Taiwan, Germany and the Netherlands. It maintains hub distribution centers in Los Angeles, Memphis and Venray, Netherlands, in addition to mid-size distribution centers in major countries.

Written from the business description in HERBALIFE LTD.'s annual report to the U.S. Securities and Exchange Commission, filed 18 February 2026. Every sentence was checked against that document before publication.

Growth

USD 5.0B

Revenue, FY2025 · full 18-year series below

Revenue $B Net income $B

FY2025 · Revenue 5.0 · Net income 0.2

Compound annual growth

Revenue

−1.1%

−1.9%

+1.2%

+4.2%

Net income

−10.8%

−9.3%

−3.9%

−1.6%

EPS, diluted

−12.0%

−4.5%

Dividend / share

−25.7%

−5.6%

Returned to shareholders

−61.8%

−61.1%

−6.8%

−19.5%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at −1.9% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

5 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 9.5% · Net 4.5%

ROE

FY2016 · ROE 364.1%

Gross margin77.9%

Operating margin9.5%

Net margin4.5%

Return on assets8.3%

EBITDAUSD 580.4M

Cash & shareholders

USD 8.2M

returned in FY2025 · dividends + net buybacks

Free cash flow $M

FY2025 · FCF 252.9

Net buybacks $B Dividends $B

FY2025 · Dividends — · Net buybacks 0.0

Dividends paid—

Net buybacksUSD 8.2M

Share of profit3.6%

Consecutive raises—

USD 8.2M in buybacks — 4% of the year's profit went back to shareholders.

Total assetsUSD 2.8B

EquityUSD -515.1M

CashUSD 353.1M

Gross debtUSD 2.0B

Net debtUSD 1.6B

Current ratio1.13×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 18-year record

18 fiscal years

Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
Revenue $B	5.0	5.0	5.1	5.2	5.8	5.5	4.9	4.9	4.4	4.5	4.5	5.0	4.8	4.1	3.5	2.7	2.3	2.4
Operating income $B	0.5	0.4	0.4	0.5	0.7	0.6	0.6	0.7	0.6	0.5	0.6	0.5	0.7	0.7	0.6	0.4	0.3	0.3
EBITDA $B	0.6	0.5	0.4	0.6	0.8	0.7	0.6	0.8	0.7	0.5	0.7	0.6	0.8	0.7	0.6	0.5	·	·
Income tax $B	0.0	−0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.1	0.1	0.1	0.2	0.2	0.1	0.1	0.1	0.1
Net income $B	0.2	0.3	0.1	0.3	0.4	0.4	0.3	0.3	0.2	0.3	0.3	0.3	0.5	0.5	0.4	0.3	0.2	0.2
Free cash flow $B	0.3	0.2	0.2	0.2	0.3	0.5	0.4	0.6	0.5	0.2	0.5	0.3	0.6	0.4	0.4	0.3	0.2	0.2
EPS, diluted $	2.20	2.50	1.42	3.23	4.13	2.77	2.20	1.98	1.29	1.51	3.97	3.40	4.91	3.94	3.32	2.32	1.61	3.36
Dividend / sh $	·	·	·	·	·	·	·	·	·	·	·	0.30	1.20	1.20	0.73	0.45	0.40	0.80
Payout %	·	·	·	·	·	·	·	0	0	0	0	10	23	29	21	18	24	23
ROE %	·	·	·	·	·	·	·	·	·	364.1	·	284.5	111.4	98.3	81.2	71.0	68.6	91.5
Shares out B	0.10	0.10	0.10	0.10	0.10	0.12	0.14	0.14	0.16	0.19	0.09	0.09	0.10	0.11	0.12	0.12	0.12	·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Herbalife Ltd.vsMckesson Corp.Same industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries Herbalife Ltd.vsCencora, Inc.Same industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries Herbalife Ltd.vsCardinal Health Inc.Same industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries Herbalife Ltd.vsNU Skin Enterprises, Inc.Same industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries Herbalife Ltd.vsCosmos Health Inc.Same industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries Herbalife Ltd.vsCellyan Biotechnology Co. Ltd.Same industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries Herbalife Ltd.vsStemtech Corp.Same industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries

Provenance

Company facts, as filed

How we verify · 0 failures in 88 reconciliationsAUDITED

Reconciled in 18 of 19 fiscal years. 7 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityWholesale-Drugs, Proprietaries & Druggists' Sundries

Listed onNYSE

Incorporated inoutside the United States — SEC code E9

Fiscal year endsDecember 31

Data on record since2008